Proven performance
Such is the efficiency of the Ranger DCB drug-delivery platform, in the COMPARE RCT, it demonstrated similar primary patency* at one year as IN.PACT DCB with just half the total drug dose.1
More confidence
Demonstrates comparable outcomes to IN.PACT with half the drug dose.1
Highest K-M Primary Patency of any DCB at 3 years
Over three years, pivotal clinical trials show the K-M primary patency rate achieved by Ranger in the Superficial Femoral Artery (SFA) is unmatched by any other Drug-coated balloon (DCB) – highlighting the superior long-term efficacy2-5 of this uniquely innovative product.
More confidence
Long term Ranger demonstrated the highest K-M Primary Patency if any DCB at 3 yeras.
Low revascularisation rate at 1 and 4 years
And what does this long-term efficacy mean for your patients?
It means you are giving them the best possible chance of avoiding the need for repeat intervention; 80% of Ranger DCB patients remain TLR-free at 4 years.6-7
More successful outcomes
Ranger demonstrated a low revascularisation rate at 1 and 4 years.
Connect with us:
References
1. Steiner S, Schmidt A, Zeller T, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41(27):2541-2552. doi:10.1093/eurheartj/ehaa049.
2. Rosenfield K, Jaff MR, White CJ, et al; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9;373(2):145–53.
3. Lyden SP, Faries PL, Niazi KAK, et al. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes. J Endovasc Ther. 2022;29(6):929–936.
4. Schneider PA, Laird JR, Tepe G, et al; IN.PACT SFA Trial Investigators. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv. 2018;11(1):e005891.
5. Brodmann M. Randomised Control Trial Data: The Pinnacle of Proof. Presented at LINC 2023, Leipzig, Germany, 6–9 June 2023.
6. RANGER II SFA Pivotal trial 12-month results presented by Marianne Brodmann. LINC 2020.
7. RANGER II SFA Pivotal trial 3 &4 years presented by Marianne Brodmann. LINC 2023.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.